INNV

Business Context and Reporting Period

Company: InnovAge Holding Corp. (INNV)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: InnovAge is the largest Program of All-Inclusive Care for the Elderly (PACE) provider in the U.S. by participant count. The company operates a vertically integrated, capitated care model for frail, dual-eligible seniors (Medicare and Medicaid). As of June 30, 2025, InnovAge served approximately 7,740 participants across 20 centers in six states (California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia). The company manages its business as a single reportable segment: PACE.

Key Financial Metrics

Note: Debt includes $60.0 million Term Loan Facility and $2.2 million Convertible Term Loan (held for sale).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 11.8% to $853.7 million, driven by a 10.3% increase in member months and a 1.4% increase in capitation rates. Growth was primarily attributed to California and Colorado centers, new de novo centers in Florida, and the acquisition of the Crenshaw center in California.
• Expense Increases: Total operating expenses rose 10.5% to $883.5 million.
  • Cost of Care: Increased 17.5% due to higher headcount, wage rates, and costs associated with in-house pharmacy services.
  • Impairments: A new line item of $13.6 million appeared in 2025 due to impairments related to halting development of a planned de novo center in Louisville, Kentucky, and losses on assets held for sale.
  • Legal Settlements: Corporate, general, and administrative expenses included a $10.1 million accrual for a securities class action lawsuit settlement.
• Profitability: While GAAP Net Loss widened to $(35.3) million, Adjusted EBITDA improved significantly by 109% to $34.5 million, reflecting the exclusion of one-time litigation costs, impairments, and stock-based compensation.
• Cash Flow: Operating cash flow swung from a use of $36.9 million in 2024 to a generation of $32.9 million in 2025, primarily due to improvements in working capital timing.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Strategy

• Growth Initiatives: The company continues to focus on increasing enrollment at existing centers, ramping up de novo centers in Florida (Tampa and Orlando), and executing tuck-in acquisitions. A joint venture with Tampa General Hospital was entered into in August 2025.
• Pharmacy Integration: In January 2025, InnovAge acquired pharmacy assets from Tabula Rasa HealthCare Group to improve cost management and support growth.
• Regulatory Impact (OBBBA): The "One Big Beautiful Bill Act" (OBBBA), enacted July 4, 2025, mandates significant reductions in federal Medicaid spending and introduces new work requirements and eligibility verifications. Management anticipates this may lead to decreased Medicaid enrollment and downward pressure on capitation rates, potentially reducing funding and margins.

Material Risks and Contingencies

• Regulatory Sanctions: The California Department of Health Care Services (DHCS) has suspended state-required attestations for planned de novo centers in Downey and Bakersfield, California, pending remediation of deficiencies found in audits of the Sacramento and San Bernardino centers. This precludes the opening of these new centers.
• Legal Proceedings:
  • Securities Litigation: A securities class action lawsuit was settled for $27.0 million (Company's share $10.1 million) in June 2025; final court approval is pending.
  • False Claims Act: The company is subject to ongoing civil investigative demands from the Department of Justice (DOJ) and the Colorado Attorney General regarding billing, patient services, and enrollment practices. Losses cannot be estimated.
  • Arbitration: An arbitration proceeding is ongoing with former pharmacy vendor Grane Rx regarding contract termination.
• Concentration Risk: Colorado, California, and Virginia accounted for approximately 86.4% of capitation revenue in 2025. The company is highly dependent on government payors (Medicare and Medicaid).

Investor Verification Checklist

• Regulatory Remediation Status: Verify the timeline and success of remediation efforts for the Sacramento and San Bernardino centers to determine if the suspended de novo centers in California can open.
• OBBBA Impact Analysis: Monitor the specific impact of the One Big Beautiful Bill Act on Medicaid enrollment rates and state capitation rate negotiations in the coming quarters.
• Legal Settlement Finalization: Confirm the final court approval of the $27.0 million securities class action settlement and any potential additional liabilities from the derivative lawsuit or DOJ investigations.
• Pharmacy Integration Costs: Assess whether the transition to in-house pharmacy services is delivering the projected cost savings against the increased operating expenses observed in 2025.
• Liquidity Position: Review the utilization of the $94.8 million remaining capacity under the Revolving Credit Facility given the company's GAAP net loss and ongoing capital requirements for growth.